On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to ret

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im

Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7

Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus

Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating a

Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consens

https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03252026_IMNN_Bautz.pdf

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial ros

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 StudyKhursheed Anwer, Ph.D.

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im

Dear Valued Shareholders,2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovar

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quart

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $

  During Thursday's session, 406 companies made new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings

  On Wednesday, 220 stocks hit new 52-week lows.

  On Monday, 76 companies set new 52-week lows.